[Pilot clinical trial of ladasten].
The psychotropic actibn and efficacy of ladasten, a new psychostimulant with anxiolitic activity, was studied in a standard clinical trial involving therapy of patients with psychogenic asthenic disorder. Ladasten exhibits a unique combination of therapeutically significant stimulant and anxiolytic effects, which is unusual of psychostimulants. At the same time, the results of ladasten action upon single administration on the dynamics of psychopatological disorders and psychological self-test indexes show that the psychostimulant action is predominating. The established combination of the psychostimulant and anxiolytic effects of ladasten is optimal for the therapy of patients with psychogenic asthenic disorders. Ladasten shows high efficacy in the treatment of these disorders testify and has good prospects for practical application.
Siuniakov
S A
SA
Grishin
S A
SA
Teleshova
E S
ES
Neznamov
G G
GG
Seredenin
S B
SB
D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001247:Asthenia / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013315:Stress, Psychological / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D000697:Central Nervous System Stimulants; C493151:N-(2-adamantyl)-N-p-bromophenylamine; D000218:Adamantane